awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33400687-4E913BC3-CD2C-4983-AF3F-1F2D729CA616
Q33400687-4E913BC3-CD2C-4983-AF3F-1F2D729CA616
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33400687-4E913BC3-CD2C-4983-AF3F-1F2D729CA616
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer
P2860
Q33400687-4E913BC3-CD2C-4983-AF3F-1F2D729CA616
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33400687-4E913BC3-CD2C-4983-AF3F-1F2D729CA616
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
a73d9bec6f9d2860c6583787af06bcace446846e
P2860
A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer.